Cargando…

Oxford-AstraZeneca COVID-19 vaccine (AZD1222) is ideal for resource-constrained low- and middle-income countries

Detalles Bibliográficos
Autores principales:	Sharun, Khan, Singh, Rajendra, Dhama, Kuldeep
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2021
Materias:	Correspondence
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8010342/ https://www.ncbi.nlm.nih.gov/pubmed/33815783 http://dx.doi.org/10.1016/j.amsu.2021.102264

Ejemplares similares

Vaccin Oxford/AstraZeneca, mode d’emploi
por: Dalmat, Yann-Mickael
Publicado: (2021)

Oxford–AstraZeneca COVID-19 vaccine efficacy
por: Knoll, Maria Deloria, et al.
Publicado: (2021)

A case of ANCA-associated vasculitis after AZD1222 (Oxford–AstraZeneca) SARS-CoV-2 vaccination: casualty or causality?
por: Villa, Miguel, et al.
Publicado: (2021)

Acute bilateral central serous chorioretinopathy in a young male after the first dose of Oxford/AstraZeneca AZD1222 (Covishield) vaccine
por: Sindhu, Meenakshi, et al.
Publicado: (2023)

Utility of skin testing in assessment of post-AZD1222 vaccine (AstraZeneca) allergic reactions: case series in Vietnam
por: Vu, Mai Thi, et al.
Publicado: (2021)

Thromboembolism and the Oxford–AstraZeneca COVID-19 vaccine: side-effect or coincidence?
por: Østergaard, Søren Dinesen, et al.
Publicado: (2021)

Who funded the research behind the Oxford–AstraZeneca COVID-19 vaccine?
por: Cross, Samuel, et al.
Publicado: (2021)

Morbilliform Eruption After Administration of Second Dose of Oxford/AstraZeneca Vaccine
por: Alhammad, Norah S, et al.
Publicado: (2022)

New relapse of multiple sclerosis and neuromyelitis optica as a potential adverse event of AstraZeneca AZD1222 vaccination for COVID-19
por: Fragoso, Yara D, et al.
Publicado: (2022)

Local myofascitis of the deltoid muscle after administration of the AstraZeneca (AZD1222) COVID-19 vaccine: two cases, infectious and inflammatory
por: Yoon, Jong Pil, et al.
Publicado: (2022)

Et de trois : l’UE recommande le vaccin AstraZeneca/Oxford
por: Manus, Jean-Marie
Publicado: (2021)

Le vaccin AstraZeneca-Oxford sur le bureau de l’EMA
por: Manus, Jean-Marie
Publicado: (2021)

Monoarthritis induced by the Oxford-AstraZeneca(R) SARS-CoV-2 vaccine
por: Schoenardie, Bruna Ossanai, et al.
Publicado: (2022)

Immunogenicity of Oxford-AstraZeneca COVID-19 Vaccine in Vietnamese Health-Care Workers
por: Chau, Nguyen Van Vinh, et al.
Publicado: (2022)

Imaging of Oxford/AstraZeneca® COVID-19 vaccine-induced immune thrombotic thrombocytopenia
por: Garnier, Matthieu, et al.
Publicado: (2021)

Large Vessel Vasculitis After the Administration of Oxford-AstraZeneca COVID-19 Vaccine
por: Katsouli, Olga K., et al.
Publicado: (2023)

SARS-CoV-2 Receptor-Binding Domain IgG Response to AstraZeneca (AZD1222) COVID-19 Vaccination, Jamaica
por: Leys, Ynolde E., et al.
Publicado: (2022)

Immune-mediated necrotizing myopathy following vaccination with the AstraZeneca (AZD1222) COVID-19 vaccine: A case report and brief review
por: Ansari, B., et al.
Publicado: (2023)

Immunoglobulin A Vasculitis Following ChadOx1 nCoV-19/AZD1222 (AstraZeneca COVID-19 Vaccine) Vaccination
por: Seo, Hyun-Min, et al.
Publicado: (2023)

COVAX Statement on WHO emergency use listing for AstraZeneca/Oxford COVID-19 vaccine
Publicado: (2021)

COVAX Statement on WHO emergency use listing for AstraZeneca/Oxford COVID-19 vaccine
Publicado: (2021)

Acute disseminated encephalomyelitis (ADEM) following recent Oxford/AstraZeneca COVID-19 vaccination
por: Permezel, Fiona, et al.
Publicado: (2021)

Oxford-AstraZeneca Coronavirus Disease-2019 Vaccine-Induced Immune Thrombocytopenia on Day Two
por: Razzaq, Azhar Kareem, et al.
Publicado: (2021)

Acquired thrombotic thrombocytopenic purpura with possible association with AstraZeneca‐Oxford COVID‐19 vaccine
por: Al‐Ahmad, Mona, et al.
Publicado: (2021)

Oxford–AstraZeneca COVID-19 vaccine: need of a reasoned and effective vaccine campaign
por: Vallée, A., et al.
Publicado: (2021)

Extensive Longitudinal Transverse Myelitis Temporally Related to the Use of AZD1222, AstraZeneca COVID-19 Vaccine: Cerebrospinal Fluid Analysis and Recent Data Review
por: da Gama, Paulo Diniz, et al.
Publicado: (2022)

AstraZeneca COVID-19 vaccine: thrombosis with thrombocytopenia
Publicado: (2021)

Anaphylaxis in Australia with AstraZeneca's COVID-19 vaccine
Publicado: (2021)

AstraZeneca COVID-19 vaccine-related thromboembolism
Publicado: (2021)

Bleeding and clotting with AstraZeneca's COVID-19 vaccine
Publicado: (2021)

Single-dose Oxford–AstraZeneca COVID-19 vaccine followed by a 12-week booster
por: Hung, Ivan F N, et al.
Publicado: (2021)

The Clinicalpathological Features of Vaccine-Induced Immune Thrombocytopenia and Thrombosis (VITT) Following ChAdOx1 (AstraZeneca AZD1222) Vaccination and Case Outcomes in Australia
por: Tran, Huyen, et al.
Publicado: (2022)

AstraZeneca COVID-19 vaccine: no increased rate of VTE
Publicado: (2021)

No increased risk of anaphylaxis with AstraZeneca COVID-19 vaccine
Publicado: (2021)

Bullous pemphigoid induced by the AstraZeneca COVID-19 vaccine
por: Agharbi, F.-Z., et al.
Publicado: (2022)

AstraZeneca COVID-19 vaccine-related thrombocytopenia and thrombosis
Publicado: (2021)

Canadian findings on AstraZeneca COVID-19 Vaccine and COVISHIELD
Publicado: (2021)

AstraZeneca COVID-19 vaccine recommended in ≥50s in Australia
Publicado: (2021)

Reactogenicity and Immunogenicity of the Pfizer and AstraZeneca COVID-19 Vaccines
por: Mahallawi, Waleed H., et al.
Publicado: (2021)

Risk-benefit of AstraZeneca COVID-19 vaccination in Australia
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_bs3c7jvak08sfd8u2aoj6e0h5v